

## DAFTAR PUSTAKA

- Adiana *et al.* (2023). *Hubungan Antara Tingkat Pendidikan dan Komorbiditas dengan Perilaku Perawatan Diri Pasien Penyakit Paru Obstruktif Kronis (PPOK)*, LPPM Itekes Bali.
- Agarwal, A. K., Raja, A., & Brown, B. D. (2023). Chronic Obstructive Pulmonary Disease. In StatPearls. StatPearls Publishing.
- Agusti A, Melen E, DeMeo DL, Breyer-Kohansal R, Faner R. (2022). Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. *Lancet Respir Med*; 10(5): 512-24.
- Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A., Jr, Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., Make, B., Marchetti, N., Martinez, F. J., Madinger, N. E., McEvoy, C., Niewoehner, D. E., Porsasz, J., Price, C. S., Reilly, J., Scanlon, P. D. (2020). COPD Clinical Research Network Azithromycin for prevention of exacerbations of COPD. *The New England journal of medicine*, 365(8), 689–698. <https://doi.org/10.1056/NEJMoa1104623>
- Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. (2016) The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development. *Am J Respir Crit Care Med*; 193(6): 662-72.
- American Thoracic Society. (2019) ATS Patient Education Series: COPD, American Thoracic Society, *Am J Respir Crit Care Med*, Vol. 199, p1-p2.
- Badan Penelitian dan Pengembangan Kesehatan (BPPK). (2018). *Riset Kesehatan Dasar*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J. (2007). Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. *Eur Respir J*; 30(4):653–661. doi: 10.1183/09031936.00004907.
- Calzetta L, Ritondo BL, Zappa MC, *et al.* (2022). The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. *Eur Respir Rev*; 31(164).
- Cazzola, M. (2015). Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbation: a meta-analysis, *Eur Respir Rev*; 24: 451-461. DOI: 10.1183/16000617.00002215.
- Celli B, Fabbri L, Criner G, *et al.* (2022). Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for its Revision. *Am J Respir Crit Care Med*.

- Ceylan E. (2006). Budesonide-formoterol (inhalation powder) in the treatment of COPD. *International journal of chronic obstructive pulmonary disease*, 1(2), 115–122. <https://doi.org/10.2147/copd.2006.1.2.115>.
- Christer Janson, Fredrik Wiklund, Gunilla Telg, Georgios Stratelis, Hanna Sandelowsky. (2023). *ERJ Open Research May*, 9 (3) 00722-2022; DOI: 10.1183/23120541.00722-2022
- Cho MH, Hobbs BD, Silverman EK. (2022) Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. *Lancet Respir Med*; 10(5): 485-96.
- Emami Ardestani, M., Kalantary, E., Samaiy, V., & Taherian, K. (2017). Methyl prednisolone vs Dexamethasone in Management of COPD Exacerbation; a Randomized Clinical Trial. *Emergency (Tehran, Iran)*, 5(1), e35.
- Viegi, G., Pistelli, F., Sherrill, D. L., Maio, S., Baldacci, S., & Carrozzi, L. (2007). Definition, epidemiology and natural history of COPD, *The European respiratory journal*, 30(5), 993–1013. <https://doi.org/10.1183/09031936.00082507>.
- GBD 2015 Chronic Respiratory Disease Collaborators (2017). Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet. Respiratory medicine*, 5(9), 91–706. [https://doi.org/10.1016/S2213-2600\(17\)30293-X](https://doi.org/10.1016/S2213-2600(17)30293-X).
- GBD Chronic Respiratory Disease Collaborators. (2020). Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet. Respiratory medicine*, 8(6), 585–596. [https://doi.org/10.1016/S2213-2600\(20\)30105-3](https://doi.org/10.1016/S2213-2600(20)30105-3).
- Goossens H, Ferech M, Vander SR, Elseviers M. (2005). Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *The Lancet*;365(9459):579–87. doi: 10.1016/S0140-6736(05)17907-0.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*, Global Obstructive Lung Disease, Inc,
- Gunen, S., et al. (2007). The role of nebulised budesonide in the treatment of exacerbations of COPD, *European Respiratory Journal*, 29; 10.1183/09031936.00073506.
- Gómez, J., Baños, V., Simarro, E., Lorenzo Cruz, M., Ruiz Gómez, J., Latour, J., Garcia Martin, E., Canteras, M., & Valdes, M. (2000). Prospective, comparative study (1994-1998) of the

influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD. *Publikasi oficial de la Sociedad Espanola de Quimioterapia*, 13(4), 379–383.

Halpin, D.M., *et al.*, Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators, *Respiratory Medicine*, 128 (28 – 41).

Hollingworth S, Kairuz T. (2021) Measuring Medicine Use: Applying ATC/DDD Methodology to Real-World Data. *Pharmacy (Basel)*;9(1):60.

Kepmenkes RI. 2022). *Panduan Praktik Klinik bagi Dokter di Fasilitas Pelayanan Kesehatan Tingkat Pertama*, Kemenkes RI, Jakarta.

Kiser, T. H., Sevransky, J. E., Krishnan, J. A., Tonascia, J., Wise, R. A., Checkley, W., Walsh, J., Sullivan, J. B., Wilson, K. C., Barker, A., Moss, M., & Vandivier, R. W. (2017). A Survey of Corticosteroid Dosing for Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Assisted Ventilation. *Chronic obstructive pulmonary diseases (Miami, Fla.)*, 4(3), 186–193. <https://doi.org/10.15326/jcopdf.4.3.2016.0168>

Larsen DL, Gandhi H, Pollack M, Feigler N, Patel S, Wise RA. (2022) The quality of care and economic burden of COPD in the United States: considerations for managing patients and improving outcomes. *Am Health Drug Benefits*; 15:57-64.

Ma, Lan-Hong., *et al.* (2023) Safety outcomes of salbutamol: A Systematic review and meta-analysis, *The Clinical Respiratory Journal*, <https://doi.org/10.1111/crj.13711>.

Madas S, Londhe J, Mudliar K, *et al.* (2022) What are the direct and indirect costs of. *COPD in India? Eur Respir J*; 60 (suppl 66): 3373.2022; 15: 57–64.

Mahmudah, F., Sumiwi, S. A., & Hartini, S. (2016). Study of the Use of Antibiotics with ATC/DDD System and DU 90% in Digestive Surgery in Hospital in Bandung. *Indonesian Journal of Clinical Pharmacy*, 5(4), 293–298. <https://doi.org/10.15416/ijcp.2016.5.4.293>.

Martinez FJ, Agusti A, Celli BR, *et al.* (2022). Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. *Am J Respir Crit Care Med*; 205(3): 275-87.

MIMS. (2024). *Metilprednisolon*. <https://www.mims.com/indonesia/drug/info/methylprednisolone?mtype=generic>

Montuschi P. (2006). Pharmacological treatment of chronic obstructive pulmonary disease. *International journal of chronic obstructive pulmonary disease*, 1(4), 409–423. <https://doi.org/10.2147/copd.2006.1.4.409>.

Naderi, *et al.* (2018) Long-term azithromycin therapy to reduce acute exacerbations in patients with

severe chronic obstructive pulmonary disease, *Clinical Trial Paper*, 5-6.  
DOI:<https://doi.org/10.1016/j.rmed.2018.03.035>.

Notoatmodjo, S. (2002). *Metodologi penelitian kesehatan*. Rineka Cipta.

Putcha, N., & Wise, R. (2018). Medication Regimens for Managing COPD Exacerbations. *Respiratory care*, 63(6), 773–782.  
<https://doi.org/10.4187/respcare.05912>.

Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. (2017). Effect of roflumilast in patients with severe COPD and a history of hospitalisation. *Eur Respir J*; 50(1).

Rehman AU, Hassali MAA, Muhammad SA, Harun SN, Shah S, Abbas S. (2020). The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. *Eur J Health Econ*; 21: 181–94.

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K. (2017.) LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis*; 12:907-922. doi: 10.2147/COPD.S130482. PMID: 28360514; PMCID: PMC5364009.

Rojas-Reyes, M. X., García Morales, O. M., Dennis, R. J., & Karner, C. (2016). Combination inhaled steroid and long-acting beta<sub>2</sub>-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews, 2016(6), CD008532.  
<https://doi.org/10.1002/14651858.CD008532.pub3>

Safka, K. A., & McIvor, R. A. (2015.) Non-pharmacological management of chronic obstructive pulmonary disease. *The Ulster medical journal*, 84(1), 13–21.

Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. (2002). Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*; (4): CD001495.

Shughrue S. (2013). *COPD Management Protocol Stanford Coordinated Care*, Stanford University, California.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C. (2019). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J*;53(5).

Singh M., et al. (2016). *Effect of low dose theophylline as adjunct in treatment of COPD*, *European Respiratory Journal*; 48. 10.1183/13993003.congress-2016.PA303

- Sjöqvist F, Birkett D. (2003). WHO Booklet Introduction to Drug Utilization Research. *Chapter 10*: *Introduction Drug Utilization*; 1:76–84.
- Sonnex K, Alleemudder H, Knaggs R. (2020). Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review. *BMJ Open*; 10(4): e037509.
- Ung, D., Dalli, L. L., Lopez, D., Sanfilippo, F. M., Kim, J., Andrew, N. E., Thrift, A. G., Cadilhac, D. A., Anderson, C. S., & Kilkenny, M. F. (2021). Assuming one dose per day yields a similar estimate of medication adherence in patients with stroke: An exploratory analysis using linked registry data. *British journal of clinical pharmacology*, 87(3), 1089–1097. <https://doi.org/10.1111/bcp.14468>
- WHO. (2023). *ATC/DDD Guidelines*, [https://www.whocc.no/atc\\_ddd\\_index\\_and\\_guidelines/guidelines/](https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/)
- WHO Internation, 2024, *Defined Daily Dose*, diakased dari <https://www.who.int/tools/atc-ddd-toolkit/about-ddd#:~:text=It%20is%20important%20to%20underline,a%20representative%20sample%20of%20prescriptions.>
- Wongsurakiat, P., Maranetra, K. N., Wasi, C., Kositanont, U., Dejsomritrutai, W., & Charoenratanakul, S. (2004). Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. *Chest*, 125(6). <https://doi.org/10.1378/chest.125.6.2011>.